Merck, Inc.
Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)
- Conditions
- Interventions
- First Posted Date
- 2023-09-14
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 160
- Registration Number
- NCT06036836
- Locations
- 🇨🇳
Taichung Veterans General Hospital-GYNECOLOGY ( Site 0033), Taichung, Taiwan
🇨🇳National Cheng Kung University Hospital-Clinical Trial Center ( Site 0032), Tainan, Taiwan
🇨🇳National Taiwan University Hospital ( Site 0031), Taipei, Taiwan
Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes
- Conditions
- Interventions
- First Posted Date
- 2023-08-24
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 14550
- Registration Number
- NCT06008756
- Locations
- 🇺🇸
Bingham Memorial Hospital ( Site 0195), Blackfoot, Idaho, United States
🇺🇸Centennial Medical Group ( Site 0179), Columbia, Maryland, United States
🇺🇸Remington-Davis, Inc. ( Site 0183), Columbus, Ohio, United States
A Study of MK-5720 in Participants With Schizophrenia (MK-5720-001)
- Conditions
- Interventions
- First Posted Date
- 2023-07-20
- Last Posted Date
- 2024-03-27
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 17
- Registration Number
- NCT05953740
- Locations
- 🇺🇸
California Clinical Trials Medical Group managed by PAREXEL ( Site 0003), Glendale, California, United States
🇺🇸Velocity Clinical Research, Hallandale Beach ( Site 0002), Hallandale Beach, Florida, United States
🇺🇸Hassman Research Institute Marlton Site ( Site 0007), Marlton, New Jersey, United States
A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-013) CORALreef Lipids
- Conditions
- Interventions
- First Posted Date
- 2023-07-19
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 2760
- Registration Number
- NCT05952856
- Locations
- 🇺🇸
Midwest Institute For Clinical Research ( Site 0059), Indianapolis, Indiana, United States
🇺🇸Center for Cardiometabolic Disease Prevention/Baylor College of Medicine ( Site 0111), Houston, Texas, United States
🇹🇷Ege Universitesi Hastanesi-Cardilogy Department ( Site 2502), Bornova, Izmir, Turkey
A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Heterozygous Familial Hypercholesterolemia (MK-0616-017) CORALreef HeFH
- Conditions
- Interventions
- First Posted Date
- 2023-07-19
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 270
- Registration Number
- NCT05952869
- Locations
- 🇸🇬
National University Hospital-Department of Medicine ( Site 3212), Singapore, Central Singapore, Singapore
🇺🇸Velocity Clinical Research at The Pioneer Heart Institute, Lincoln ( Site 0026), Lincoln, Nebraska, United States
🇧🇷Incor - Instituto do Coracao ( Site 0703), Sao Paulo, Brazil
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
- First Posted Date
- 2023-07-17
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 720
- Registration Number
- NCT05947851
- Locations
- 🇹🇷
Mega Medipol-Hematology ( Site 4904), İstanbul, Turkey
🇺🇸Highlands Oncology Group ( Site 5405), Springdale, Arkansas, United States
🇺🇸MemorialCare Health System - Long Beach Medical Center ( Site 5421), Long Beach, California, United States
A Clinical Study of V940 Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)
- Conditions
- Interventions
- First Posted Date
- 2023-07-06
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1089
- Registration Number
- NCT05933577
- Locations
- 🇨🇳
Chang Gung Memorial Hospital at Kaohsiung (Site 4000), Kaohsiung, Taiwan
🇨🇳National Cheng Kung University Hospital-Clinical Trial Center ( Site 4004), Tainan, Taiwan
🇨🇳National Taiwan University Hospital (Site 4001), Taipei, Taiwan
Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Renal Impairment Study 2 (MK-0616-020)
- First Posted Date
- 2023-07-06
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 33
- Registration Number
- NCT05934292
- Locations
- 🇺🇸
Advanced Pharma CR, LLC ( Site 0001), Miami, Florida, United States
🇺🇸Clinical Pharmacology of Miami ( Site 0005), Miami, Florida, United States
🇺🇸Velocity Clinical Research, Hallandale Beach ( Site 0003), Hallandale Beach, Florida, United States
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study
- Conditions
- Interventions
- First Posted Date
- 2023-06-12
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 249
- Registration Number
- NCT05899049
- Locations
- 🇨🇳
Beijing Cancer hospital-Renal carcinoma and melanoma ( Site 6000), Beijing, Beijing, China
🇨🇳Chongqing University Cancer Hospital ( Site 6009), Chongqing, Chongqing, China
🇨🇳SUN YAT-SEN UNIVERSITY CANCER CENTRE ( Site 6003), Guangzhou, Guangdong, China
A Study To Evaluate The Effect Of A Supratherapeutic Dose Of MK-8189 On The QTc Interval In Participants With Schizophrenia (MK-8189-019)
- First Posted Date
- 2023-06-08
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 107
- Registration Number
- NCT05893862
- Locations
- 🇺🇸
California Clinical Trials Medical Group managed by PAREXEL-PAREXEL International ( Site 0003), Glendale, California, United States
🇺🇸Hassman Research Institute Marlton Site ( Site 0001), Marlton, New Jersey, United States
🇺🇸NRC Research Institute ( Site 0004), Orange, California, United States